Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis
出版年份 2021 全文链接
标题
Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis
作者
关键词
-
出版物
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2021-11-17
DOI
10.1093/ndt/gfab332
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2020) Arshad M. Khanani et al. JAMA Ophthalmology
- Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
- (2020) Majid Khan et al. Cells
- Endothelium structure and function in kidney health and disease
- (2019) Noemie Jourde-Chiche et al. Nature Reviews Nephrology
- Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
- (2019) Jessica Gillen et al. Current Oncology Reports
- Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
- (2019) Jayashree Sahni et al. OPHTHALMOLOGY
- Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
- (2019) Rehan M. Hussain et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Angiopoietin‐Tie signaling in kidney diseases: an updated review
- (2019) Fang‐Fang He et al. FEBS LETTERS
- Role of melatonin in controlling angiogenesis under physiological and pathological conditions
- (2019) Qiang Ma et al. ANGIOGENESIS
- Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in murine non-alcoholic fatty liver disease
- (2018) Sander Lefere et al. HEPATOLOGY
- Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
- (2018) Seung-Jun Lee et al. JOURNAL OF CLINICAL INVESTIGATION
- The Angiopoietin-Tie2 Signaling Axis in Systemic Inflammation
- (2017) Samir M. Parikh JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
- (2016) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease
- (2016) Yi-Chun Tsai et al. Scientific Reports
- Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease
- (2015) Yi-Chun Tsai et al. PLoS One
- Effects of an anabolic steroid (Durateston) on testicular angiogenesis in peripubertal stallions
- (2015) A. Teubner et al. THERIOGENOLOGY
- Endothelial destabilization by angiopoietin-2 via integrin β1 activation
- (2015) Laura Hakanpaa et al. Nature Communications
- A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
- (2014) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population
- (2013) Roberto Lorbeer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Divergent regulation of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor by hypoxia and female sex steroids in human endometrial stromal cells
- (2013) Tomoko Tsuzuki et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Angiopoietin-2 levels predict mortality in CKD patients
- (2011) Sascha David et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia
- (2010) Brunna E Alves et al. BMC INFECTIOUS DISEASES
- Clinical and Genetic Correlates of Circulating Angiopoietin-2 and Soluble Tie-2 in the Community
- (2010) Wolfgang Lieb et al. Circulation-Cardiovascular Genetics
- Circulating angiopoietin-2 levels increase with progress of chronic kidney disease
- (2010) S. David et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation
- (2009) Sascha David et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function
- (2009) Wolfgang Lieb et al. EUROPEAN HEART JOURNAL
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin
- (2009) Sascha David et al. JOURNAL OF HYPERTENSION
- Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study–74)
- (2009) Sathish Anuradha et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus
- (2008) P Kumpers et al. ANNALS OF THE RHEUMATIC DISEASES
- Balance between Angiopoietin-1 and Angiopoietin-2 Is in Favor of Angiopoietin-2 in Atherosclerotic Plaques with High Microvessel Density
- (2008) Simone Post et al. JOURNAL OF VASCULAR RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started